06.28.24 -- Navigate The Current Outsourcing Landscape With Ease And Connect With Top CDMOs

Learn more about our integrated offerings in mammalian drug substance and drug product. Our drug product (Fill & Finish) services cover vials (LivI, Lyo), syringes (PFS), Cartrdiges and Auto Injectors.

Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Hear about how we can support manufacturing programs from clinical through commercial.

We are a sustainable partner in the commercial manufacturing of your liquid products. To advance therapeutic and prophylactic therapies, we have set up state-of-the-art high-speed filling capacities.

Senior Business Development Manager, Christine Rodi, highlights our overall sterile injectable drug substance capabilities, with a focus on our ability to help meet your complex sterile injectable needs.

We are a CGT focused division of New York Blood Center Enterprises with a Draw-To-Thaw™ portfolio of CDMO services strategically located throughout the US built upon on NYBC’s 60+ years of experience.

With a strong network of 11 sites located across North America supporting 5 modalities, Resilience provides innovative solutions and services for established and emerging therapies.

Discover how we apply our 30 years of experience to enhance quality, de-risk viral vector production at any stage, and advance cell and gene therapies from pre-IND through routine supply.

Examine the time saving factor of using Cellistic's predeveloped Pulse & Echo platforms, the IP considerations with iPCSs, and Cellistic's involvement in developing clinical therapies.

Learn how our proven methodology and decades-long AAV database at the core of the AAV Curator™ Platform directly drives speed, maximizes yields, and delivers a high-quality product.

Review our gene & cell therapy capabilities, with a focus on our ability to help meet your complex viral vector needs by employing cutting edge technology with industry leading yield & productivity ratios.

Review an update on our 400,000+ square foot campus in Philadelphia, Pennsylvania and the infrastructure dedicated to Cell & Gene Therapy development, testing and manufacturing.

Explore the new capacity and capabilities of our complete mRNA Ecosystem to offer streamlined services for process development, manufacture, and release of both mRNA drug substance and product.

Examine our platform analytical and process technologies designed to accelerate the development of your cell therapy, gene therapy, or vaccine drug product.

Learn more about our global capabilities in Nucleic Acid, AAV, Lentivirus, Microbiome and Fill-Finish. We offer end-to-end GMP manufacturing under one roof through an integrated supply chain.

Gain insight into our proprietary digital platform that de-risks clinical trials, expedites manufacturing, offers full transparency to sponsors, and provides complete chain-of-custody assurance.